Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

Purifying novel therapeutics remains a major challenge as increasingly complex molecules move towards the clinic. With Lonza, you can ensure optimal product quality and bring your molecules to the ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

The two main fixation formats used by researchers are formalin fixation followed by paraffin embedding (FFPE) or snap-frozen in liquid nitrogen (referred to as Fresh Frozen or FF). There is less of a ...

This session will explore how integrating Ready Made Solutions can help streamline downstream bioprocessing by reducing complexity and increasing efficiency for MSAT and production teams. Together, ...

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...